Usnoflast

Usnoflast is the selective, orally active inhibitor for NLRP3 that blocks the release of IL-1β, and exhibits anti-inflammatory activity[1][2].

Product Specifications

CAS Number

[2455519-86-3]

UNSPSC

12352005

Target

NOD-like Receptor (NLR)

Type

Reference compound

Related Pathways

Immunology/Inflammation

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology; Neurological Disease

Assay Protocol

https://www.medchemexpress.com/usnoflast.html

Purity

98.29

Solubility

DMSO : 62.5 mg/mL (ultrasonic; warming; heat to 60°C)

Smiles

C[C@]1(N(CCC1)C)/C=C/S(NC(NC2=C3C(CCC3)=CC4=C2CCC4)=O)(=O)=O

Molecular Formula

C21H29N3O3S

Molecular Weight

403.54

References & Citations

[1]Sharma, et al. Novel substituted sulfonylurea derivatives as NLRP3 modulators and their preparation. World Intellectual Property Organization, WO2020148619 A1. 2020-07-23.|[2]Chatterjee A, et al., A novel selective NLRP3 inhibitor shows disease-modifying potential in animal models of Parkinson's disease. Brain Res. 2024 Nov 1;1842:149129.